Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
281.99 USD   -0.22%
11/28Amgen to webcast investor call at wcirdc 2022
PR
11/24U.S. Supreme Court To Decide On Enablement Standard For Biotech Antibody Patents In Amgen v. Sanofi
AQ
11/23Amgen announces webcast of 2022 evercore isi healthcare conference
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds
Most relevant news about AMGEN INC.
11/28Amgen to webcast investor call at wcirdc 2022
PR
11/24U.S. Supreme Court To Decide On Enablement Standard For Biotech Antibody Patents In Amg..
AQ
11/23Amgen announces webcast of 2022 evercore isi healthcare conference
PR
11/22Amgen's Osteoporosis Drug Prolia Faces US FDA Probe Over Risk of Severe Hypocalcemia in..
MT
11/22Amgen's Osteoporosis Drug Prolia Faces US FDA Probe Over Risk of Severe Hypocalcemia in..
MT
11/18Credit Suisse Starts Amgen at Underperform With $240 PT, Says Recent Performance Not Re..
MT
11/17USSC Agrees To Reconsider Amgen Inc. V Sanofi On Enablement Of Antibody Genus Claims
AQ
11/16AMGEN INC. : Ex-dividend day for
FA
11/15Novo Nordisk CEO Unfazed By Imminent Entry of Rival Obesity Drugs from Amgen, Lilly
MT
11/15Looming obesity drug rivalry not a concern for Novo CEO
RE
11/14Supreme Court To Consider Enablement Requirement
AQ
11/11Amgen v. Sanofi Case On Enablement Of Antibody Genus Claims Will Be Heard At The Suprem..
AQ
11/10Amgen : Latest Acquisition Puts a Spotlight on Rare Autoimmune Disease
PU
11/09Supreme Court To Address What It Means To Have An Enabling Disclosure
AQ
11/09Transcript : Amgen Inc. Presents at Credit Suisse 31st Annual Healthcare Conf..
CI
More most relevant news
All news about AMGEN INC.
11/28Amgen to webcast investor call at wcirdc 2022
PR
11/24U.S. Supreme Court To Decide On Enablement Standard For Biotech Antibody Patents In Amg..
AQ
11/23Amgen announces webcast of 2022 evercore isi healthcare conference
PR
11/22Amneal Pharmaceuticals Launches Releuko for Neutropenia in US
MT
11/22Mirati attracts fresh takeover interest - Bloomberg News
RE
11/22Amgen's Osteoporosis Drug Prolia Faces US FDA Probe Over Risk of Severe Hypocalcemia in..
MT
11/22Generic drugmakers Teva and Sandoz make major push to biosimilars
RE
11/22Amgen's Osteoporosis Drug Prolia Faces US FDA Probe Over Risk of Severe Hypocalcemia in..
MT
11/22CORRECTED (OFFICIAL) -FOCUS-Generic drugmakers Teva and Sandoz make major push to biosi..
RE
11/21MarketScreener's World Press Review : November 21, 2..
MS
More news
News in other languages on AMGEN INC.
11/22Amneal Pharmaceuticals lance Releuko pour la neutropénie aux États-Unis
11/22Prolia, le médicament contre l'ostéoporose d'Amgen, fait l'objet d'une enquête de la FD..
11/22Prolia, le médicament d'Amgen contre l'ostéoporose, fait l'objet d'une enquête de la FD..
11/21Wall Street ouvre en baisse, à l'orée d'une semaine écourtée
11/21Du mouvement chez Disney, les bénéfices de Valloure..
11/18USA-Les valeurs à suivre à Wall Street (actualisé)
11/15La filiale de Heritage Global renouvelle l'accord pour vendre les actifs excédentaires ..
11/15Le PDG de Novo Nordisk ne s'inquiète pas de l'arrivée imminente des médicaments rivaux ..
11/15La competencia en medicamentos contra la obesidad no preocupa al presidente de Novo
11/14Borsa Usa, Nasdaq guida Wall Street al ribasso dopo commenti "hawkish" Fed
More news
Analyst Recommendations on AMGEN INC.
11/18Credit Suisse Starts Amgen at Underperform With $240 PT, Says Recent Performance Not Re..
MT
11/18Analyst recommendations: AbbVie, Bristol-Myers, Dominion Energy,..
MS
11/09DA Davidson Adjusts Amgen Price Target to $310 From $275, Maintains Buy Rating
MT
11/08Oppenheimer Adjusts Amgen Price Target to $300 From $290, Maintains Outperform Rating
MT
11/07UBS Adjusts Amgen Price Target to $271 From $257, Maintains Neutral Rating
MT
More recommendations
Press releases
11/28Amgen to webcast investor call at wcirdc 2022
PR
11/24U.S. Supreme Court To Decide On Enablement Standard For Biotech Antibody Patents In Amg..
AQ
11/23Amgen announces webcast of 2022 evercore isi healthcare conference
PR
11/17USSC Agrees To Reconsider Amgen Inc. V Sanofi On Enablement Of Antibody Genus Claims
AQ
11/14Supreme Court To Consider Enablement Requirement
AQ
More press releases
Upcoming event on AMGEN INC.